Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) major shareholder Proquest Investments Iv, L.P. sold 34,486 shares of the company’s stock in a transaction on Friday, November 11th. The shares were sold at an average price of $85.15, for a total transaction of $2,936,482.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Proquest Investments Iv, L.P. also recently made the following trade(s):

  • On Monday, November 7th, Proquest Investments Iv, L.P. sold 5,030 shares of Eagle Pharmaceuticals stock. The shares were sold at an average price of $75.39, for a total transaction of $379,211.70.
  • On Wednesday, November 9th, Proquest Investments Iv, L.P. sold 153,830 shares of Eagle Pharmaceuticals stock. The shares were sold at an average price of $79.29, for a total transaction of $12,197,180.70.
  • On Friday, November 4th, Proquest Investments Iv, L.P. sold 245,770 shares of Eagle Pharmaceuticals stock. The shares were sold at an average price of $71.02, for a total transaction of $17,454,585.40.
  • On Friday, September 30th, Proquest Investments Iv, L.P. sold 22,100 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $70.06, for a total transaction of $1,548,326.00.
  • On Thursday, September 29th, Proquest Investments Iv, L.P. sold 77,900 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $70.04, for a total transaction of $5,456,116.00.
  • On Wednesday, September 21st, Proquest Investments Iv, L.P. sold 99,795 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $66.17, for a total transaction of $6,603,435.15.
  • On Thursday, September 8th, Proquest Investments Iv, L.P. sold 70,925 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $62.50, for a total transaction of $4,432,812.50.
  • On Wednesday, August 24th, Proquest Investments Iv, L.P. sold 28,870 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $63.00, for a total transaction of $1,818,810.00.
  • On Tuesday, August 16th, Proquest Investments Iv, L.P. sold 60,150 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $61.67, for a total transaction of $3,709,450.50.
  • On Wednesday, August 17th, Proquest Investments Iv, L.P. sold 99,795 shares of Eagle Pharmaceuticals stock. The stock was sold at an average price of $61.36, for a total transaction of $6,123,421.20.

Shares of Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) opened at 81.98 on Wednesday. Eagle Pharmaceuticals Inc. has a 52 week low of $33.02 and a 52 week high of $102.48. The company has a 50-day moving average of $68.45 and a 200-day moving average of $54.53. The firm has a market capitalization of $1.27 billion, a PE ratio of 53.37 and a beta of 1.37.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings data on Wednesday, November 9th. The specialty pharmaceutical company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.12. The firm earned $37.80 million during the quarter, compared to the consensus estimate of $41.04 million. Eagle Pharmaceuticals had a net margin of 20.06% and a return on equity of 25.63%. The firm’s revenue was up 563.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.65) earnings per share. On average, equities analysts forecast that Eagle Pharmaceuticals Inc. will post $4.54 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

A number of equities analysts have commented on EGRX shares. Zacks Investment Research downgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Friday, July 22nd. Mizuho upgraded shares of Eagle Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $62.00 to $78.00 in a research report on Thursday, November 3rd. RBC Capital Markets restated an “outperform” rating and set a $93.00 price objective on shares of Eagle Pharmaceuticals in a research report on Monday. Piper Jaffray Cos. restated a “buy” rating and set a $91.00 price objective on shares of Eagle Pharmaceuticals in a research report on Saturday, October 15th. Finally, William Blair upped their price target on shares of Eagle Pharmaceuticals from $83.00 to $97.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 2nd. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Eagle Pharmaceuticals has an average rating of “Buy” and a consensus target price of $90.24.

Institutional investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. acquired a new position in Eagle Pharmaceuticals during the third quarter worth approximately $48,318,000. First Eagle Investment Management LLC bought a new stake in Eagle Pharmaceuticals during the third quarter worth about $39,774,000. BlackRock Fund Advisors boosted its stake in Eagle Pharmaceuticals by 87.0% in the third quarter. BlackRock Fund Advisors now owns 769,869 shares of the specialty pharmaceutical company’s stock worth $53,891,000 after buying an additional 358,134 shares during the last quarter. State Street Corp boosted its stake in Eagle Pharmaceuticals by 64.3% in the first quarter. State Street Corp now owns 629,493 shares of the specialty pharmaceutical company’s stock worth $25,489,000 after buying an additional 246,262 shares during the last quarter. Finally, Bank of Montreal Can bought a new stake in Eagle Pharmaceuticals during the second quarter worth about $5,356,000.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).

5 Day Chart for NASDAQ:EGRX

Receive News & Stock Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.